Aimmune Therapeutics to Present at Three Investor Conferences in September
August 29 2018 - 8:00AM
Business Wire
- Wells Fargo Healthcare Conference,
September 5
- Baird Global Healthcare Conference,
September 6
- Bank of America Merrill Lynch Global
Healthcare Conference, September 12
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical
company developing treatments for life-threatening food allergies,
today announced that members of senior management will present at
three investor conferences in September:
Wells Fargo Healthcare Conference
Date: September 5, 2018
Time: 1:50 p.m. Eastern Time
Location: Boston
Presenter: Jayson Dallas, M.D., President and CEO
Baird Global Healthcare Conference
Date: September 6, 2018
Time: 10:15 a.m. Eastern Time
Location: New York
Presenter: Jayson Dallas, M.D., President and CEO
Bank of America Merrill Lynch Global Healthcare
Conference
Date: September 12, 2018
Time: To be assigned; time will be posted on www.aimmune.com on
the Events page under the Investor Relations section when
available
Location: London
Presenter: Eric Bjerkholt, CFO
Live webcasts of each presentation will be accessible on the
Events page under the Investor Relations section of the Aimmune
website at www.aimmune.com. Replays of the webcasts will be
available for at least 30 days following each webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company
developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to provide meaningful levels of protection
against allergic reactions resulting from accidental exposure to
food allergens by desensitizing patients with defined, precise
amounts of key allergens. Aimmune’s first investigational biologic
product using CODIT™, AR101 for the treatment of peanut allergy,
has received the FDA’s Breakthrough Therapy Designation for the
desensitization of peanut-allergic patients 4-17 years of age.
Aimmune plans to submit regulatory filings for marketing approval
of AR101 in the United States and Europe based on data from the
pivotal Phase 3 PALISADE clinical trial of AR101, which in 4-17
year-old subjects met its primary and key secondary endpoints, and
expects results from additional ongoing and completed AR101
clinical trials. For more information, please see
www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by
the U.S. Food and Drug Administration (FDA) or the European
Medicines Agency (EMA). It is currently limited to investigational
use, and no representation is made as to its safety or
effectiveness for the purposes for which it is being
investigated.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180829005221/en/
Contacts:InvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2023 to Apr 2024